Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close. A conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET.
According to Halozyme, the call requires pre-registration and will be available via live webcast and replay in the company's Investors section at www.halozyme.com.
Halozyme (Nasdaq: HALO) appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove brings more than 30 years of financial leadership, including roles leading investor relations at Johnson & Johnson and serving as CFO for J&J's Pharmaceuticals business, a unit generating over $50 billion in annual revenue.
Halozyme (Nasdaq: HALO) announced a global exclusive collaboration and license with Vertex Pharmaceuticals on April 7, 2026 to apply Halozyme's Hypercon™ microparticle technology to up to three drug targets. Vertex will pay a $15 million upfront, potential future milestones, and royalties on net sales.
The agreement aims to reduce injection volume and enable at-home dosing for biologics through Hypercon's hyperconcentration capability.
Halozyme (NASDAQ: HALO) named David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay will oversee all financial operations while the company continues its search for a permanent CFO.
He brings more than 30 years of biotech financial leadership and previously served as Halozyme CFO from 2003–2009 and 2013–2015. Halozyme has engaged a leading executive search firm to identify a permanent CFO; Ramsay will remain until an appointment is made.
Halozyme (NASDAQ: HALO) announced that Johnson & Johnson received U.S. FDA approval (March 6, 2026) for TECVAYLI (teclistamab) combined with DARZALEX FASPRO for adults with relapsed/refractory multiple myeloma after ≥1 prior therapy. The approval followed Phase 3 MajesTEC-3 data showing statistically significant PFS and OS benefits.
Key trial results: hazard ratio 0.17 for progression or death (95% CI 0.12–0.23; P<0.0001) and a three-year PFS rate of 83% after median three-year follow-up.
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will present and hold investor meetings at three upcoming conferences: TD Cowen on March 3, 2026, Leerink on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026.
Live audio webcasts will be available on the company investor relations website, with replays accessible for 90 days after each event.
Halozyme (NASDAQ: HALO) reported record full‑year 2025 total revenue of $1.397 billion, driven by $867.8 million in royalties (+52% YoY). The company completed acquisitions of Elektrofi (Hypercon) and Surf Bio, issued convertible notes, and reiterated 2026 guidance: $1.71–$1.81B revenue, $1.125–$1.205B adjusted EBITDA, and $7.75–$8.25 non‑GAAP EPS.
Net income was $316.9M (includes $284.9M acquired IPR&D); cash and equivalents declined to $145.4M.
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.
Halozyme (Nasdaq: HALO) raised its outlook after strong 2025 momentum, updating preliminary 2025 revenue to $1,385–$1,400M (36–38% YoY) and royalty revenue to $865–$870M (51–52% YoY). For 2026 the company raised guidance to $1,710–$1,810M total revenue and $1,130–$1,170M royalties, with adjusted EBITDA of $1,125–$1,205M and non-GAAP EPS of $7.75–$8.25. Halozyme acquired Surf Bio for an upfront $300M (up to $400M total) to add hyperconcentration technology enabling formulations up to 500 mg/mL.
Nootropics Depot (HALO) corrected its Sept. 16, 2025 release to report that its High Potency Saffron Extract capsules are standardized to 7.5% crocins and 1% safranals, claiming the highest measured concentrations among tested supplements.
Independent and ISO‑accredited HPLC testing reportedly shows the product contains 1.97x more crocins and 1.18x more safranal per capsule versus the next competitor; manufacturing occurs in cGMP and FDA‑registered facilities in Arizona, with batch COAs publicly available.